Endobronchial Zephyr valves for bronchoscopic lung volume reduction for severe emphysema: a systematic review and meta-analysis
Authors:
- Yub Raj SehdaiYSYub Raj Sehdai
- Hassnain Mbbs AwanHAHassnain Mbbs Awan
- Faisal Mbbs ChowdhuryFaisal Mbbs Chowdhury
- Abdelmonem Mbbs SiddiqASAbdelmonem Mbbs Siddiq
- Sajina Mbbs ShresthaSSSajina Mbbs Shrestha
- Harendra SinghHSHarendra Singh
- Sanskriti Mbbs ChapagainSCSanskriti Mbbs Chapagain
- Sneha KhanalSKSneha Khanal
- Suman Mbbs KadariyaSKSuman Mbbs Kadariya
- Sushil RayamajhiSRSushil Rayamajhi
Open Access
- 16 June 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4467-4475
Abstract
Background: Chronic obstructive pulmonary disease (COPD) causes permanent lung damage and is a global health issue. Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr valves has increased COPD treatment choices for individuals with persistent symptoms despite maximal drug therapy. Objectives: This systematic review and meta-analysis evaluated available Zephyr valve data in severe emphysema patients. Data and methods: We searched Cochrane, PubMed, Google Scholar, Lilacs, and Science Direct extensively and included eight randomized control trials (RCTs). Results: This meta-analysis comprises 1083 patients 669 Zephyr valve-treated and 414 control. The mean difference in 6-minute walking distance was 37.53 meters (95% CI: 22.14–52.90, P < 0.001). Statistically significant improvements were also observed in FEV1 predicted percentage (mean difference: 13.64, 95% CI: 8.51–18.77, P < 0.001) and BODE index change (mean difference: −0.79, 95% CI: −1.33 to 0.26, P < 0.05), mMRC dyspnea scale (mean difference: −0.27, 95% CI: −0.55 to 0.02, P < 0.01) and residual volume (mean difference: −0.14, 95% CI: −0.64 to 0.35, P < 0.01). The quality of life measured by SGRQ also improved significantly (mean difference: −6.69, 95% CI: −9.69, −4.23, P < 0.001). While COPD exacerbation rates (OR:1.41, 95% CI: 0.87–2.30, P > 0.05) and pneumonia rates (OR: 1.72, 95% CI: 0.7–4.23, P > 0.05) were similar between valve and control groups, pneumothorax risk was significantly higher in the treatment arm (OR: 11.06, 95% CI: 4.10–29.80, P < 0.001). However, there was no significant difference in all-cause mortality between the groups (OR: 1.69; 95% CI: 0.53–5.38, P > 0.38). Conclusion: Zephyr valves may improve lung function, exercise capacity, and quality of life in patients suffering from severe emphysema. However, the increased risk of pneumothorax requires careful patient selection and rigorous post-intervention monitoring.Keywords
This publication has 36 references indexed in Scilit:
- Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling studyThe Lancet Global Health, 2023
- GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologistsClinical Research in Cardiology, 2023
- Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysisThe Lancet Respiratory Medicine, 2022
- Global Impact of Respiratory DiseaseChest, 2022
- Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Respiratory Medicine, 2020
- Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysisThe Lancet Respiratory Medicine, 2019
- Bronchoscopic Lung Volume ReductionSeminars in Thoracic and Cardiovascular Surgery, 2010
- Bronchoscopic Lung-Volume Reduction With One-Way Valves in Patients With Heterogenous EmphysemaThe Annals of Thoracic Surgery, 2005
- Bronchoscopic volume reduction with valve implants in patients with severe emphysema.The Lancet, 2003